Harmony Biosciences Holdings, Inc. $HRMY Shares Purchased by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd boosted its stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 271.4% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 147,044 shares of the company’s stock after buying an additional 107,449 shares during the period. Y Intercept Hong Kong Ltd owned approximately 0.25% of Harmony Biosciences worth $4,119,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of HRMY. Robeco Institutional Asset Management B.V. increased its position in shares of Harmony Biosciences by 0.6% during the fourth quarter. Robeco Institutional Asset Management B.V. now owns 47,085 shares of the company’s stock valued at $1,762,000 after acquiring an additional 298 shares during the last quarter. Nebula Research & Development LLC lifted its holdings in shares of Harmony Biosciences by 2.0% in the 2nd quarter. Nebula Research & Development LLC now owns 17,403 shares of the company’s stock worth $550,000 after acquiring an additional 348 shares during the last quarter. The Manufacturers Life Insurance Company boosted its position in shares of Harmony Biosciences by 2.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,686 shares of the company’s stock worth $717,000 after purchasing an additional 532 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Harmony Biosciences by 25.9% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,799 shares of the company’s stock worth $105,000 after purchasing an additional 575 shares during the period. Finally, Allworth Financial LP increased its holdings in Harmony Biosciences by 286.7% in the 4th quarter. Allworth Financial LP now owns 812 shares of the company’s stock valued at $30,000 after purchasing an additional 602 shares during the last quarter. Institutional investors and hedge funds own 86.23% of the company’s stock.

Harmony Biosciences Price Performance

Shares of NASDAQ:HRMY opened at $37.26 on Monday. The firm’s 50 day moving average price is $32.54 and its 200 day moving average price is $32.83. The stock has a market cap of $2.16 billion, a price-to-earnings ratio of 15.02, a price-to-earnings-growth ratio of 0.35 and a beta of 0.94. Harmony Biosciences Holdings, Inc. has a fifty-two week low of $25.52 and a fifty-two week high of $40.87. The company has a quick ratio of 3.56, a current ratio of 3.58 and a debt-to-equity ratio of 0.15.

Harmony Biosciences (NASDAQ:HRMY) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.55 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.21). Harmony Biosciences had a return on equity of 17.19% and a net margin of 16.20%.The firm had revenue of $215.39 million during the quarter, compared to analysts’ expectations of $220.84 million. During the same quarter in the prior year, the firm earned $0.78 EPS. The firm’s revenue was up 16.6% compared to the same quarter last year. As a group, equities research analysts predict that Harmony Biosciences Holdings, Inc. will post 3.26 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on HRMY shares. Zacks Research upgraded Harmony Biosciences from a “strong sell” rating to a “hold” rating in a report on Friday, May 1st. Weiss Ratings raised shares of Harmony Biosciences from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, June 23rd. Truist Financial raised their price objective on shares of Harmony Biosciences from $25.00 to $29.00 and gave the company a “hold” rating in a research note on Friday, May 8th. Deutsche Bank Aktiengesellschaft upped their target price on shares of Harmony Biosciences from $30.00 to $36.00 and gave the stock a “hold” rating in a research note on Tuesday, June 30th. Finally, HC Wainwright reissued a “buy” rating on shares of Harmony Biosciences in a research report on Wednesday, June 24th. Four research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Harmony Biosciences presently has an average rating of “Hold” and a consensus target price of $41.44.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.